蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1910|回复: 6
收起左侧

2015财年FDA公布的前十大缺陷

[复制链接]
药生
发表于 2017-9-5 17:11:36 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
Cite Id
Reference Number
Short Description
Long Description
Frequency

1105
21 CFR 211.22(d)
Procedures not in writing, fully followed 程序没有书面化,没有完全遵守
The responsibilities and procedures applicable to the quality control unit are not [in writing] [fully followed]. Specifically, *** 应用于质量控制部门的职责和程序没有【书面化】【完全遵守】。例如。。。。      
160

3603
21 CFR 211.160(b)
Scientifically sound laboratory controls科学合理的化验室控制     
Laboratory controls do not include the establishment of scientifically sound and appropriate [specifications] [standards] [sampling plans] [test procedures] designed to assure that [components] [drug product containers] [closures] [in-process materials] [labeling] [drug products] conform to appropriate standards of identity, strength, quality and purity.  Specifically, ***化验室控制未包括科学合理的设施和适当的【质量标准】【规格】【取样计划】【检测方法】,用于保证【成分】【药品容器】【容器】【中控物料】【标识】【药品】符合适当的鉴别、剂量、质量和纯度标准。例如。。。。   
130

2027
21 CFR 211.192
Investigations of discrepancies, failures不符合性、失败调查
There is a failure to thoroughly review [any unexplained discrepancy] [the failure of a batch or any of its components to meet any of its specifications] whether or not the batch has been already distributed.  Specifically, ***未能彻底审核【所有未能解释的不符合性】【批次不合格或其组成不符合其质量标准】,有些批次已销售。例如。。。
124

1451
21 CFR 211.113(b)
Procedures for sterile drug products无菌药品的程序  
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not [established] [written] [followed].  Specifically, ***未【建立】【书面化】【遵守】设计用于防止无菌药品微生物污染的程序。例如。。。
104

1361
21 CFR 211.100(a)
Absence of Written Procedures 缺失书面程序  
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.  Specifically, ***生产和工艺控制没有设计书面程序,用以保证药品应具备的鉴别、剂量、质量和纯度。例如。。。
95

1434
21 CFR 211.42(c)(10)(iv)
Environmental Monitoring System环境监控系统
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.  Specifically, ***无菌工艺区域饿环境条件监控系统不足,例如。。。
83

1883
21 CFR 211.165(a)
Testing and release for distribution检测和放行销售
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the [final specifications] [identity and strength of each active ingredient] prior to release.  Specifically, ***在放行前,药品的检测和放行销售未包括适当的化验室对【最终质量标准】【每一种活性物质鉴别和剂量】的测试。例如。。。
80

3585
21 CFR 211.110(a)
Control procedures to monitor and validate performance监控和验证性能的控制程序
Control procedures are not established which [monitor the output] [validate the performance] of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.  Specifically, ***没有确立控制程序来监控生产过程的输出、验证性能,可能导致中间产品和药品的品质的差异。
69

1213
21 CFR 211.67(a)
Cleaning / Sanitizing / Maintenance清洁/消毒/维护
Equipment and utensils are not [cleaned] [maintained] [sanitized] at appropriate intervals to  prevent [malfunctions] [contamination] that would alter the safety, identity, strength, quality or purity of the drug product.  Specifically, ***设备和工器具未按适当的周期【清洁】【维护】【消毒】,以防止可能会对药品的质量或纯度、安全、鉴别、剂量产生负面影响的【误操作】【污染】。例如。。。
68

1274
21 CFR 211.68(a)
Calibration/Inspection/Checking not done校验/检查/核对
Routine [calibration] [inspection] [checking] of  [automatic] [mechanical] [electronic] equipment is not performed according to a written program designed to assure proper performance.  Specifically, ***自动化】【机械的】【电子的】设备没有根据书面程序来进行日常【校正】【检查】【核查】。该书面程序应设计以保证其适当工作。例如。。。
64

1914
21 CFR 211.166(a)
Lack of written stability program
There is no written testing program designed to assess the stability characteristics of drug products.  Specifically, ***
63

1435
21 CFR 211.42(c)(10)(v)
Cleaning System
Aseptic processing areas are deficient regarding the system for cleaning  and disinfecting the [room] [equipment] to produce aseptic conditions.  Specifically, ***
60

本帖被以下淘专辑推荐:

回复

使用道具 举报

药士
发表于 2017-9-5 18:50:41 | 显示全部楼层
了解一下
回复

使用道具 举报

药徒
发表于 2017-9-5 22:44:55 | 显示全部楼层
15年的总结?
出处是哪里?

点评

FDA官网  详情 回复 发表于 2017-9-6 21:09
回复

使用道具 举报

药生
 楼主| 发表于 2017-9-6 21:09:27 | 显示全部楼层
工作QQ 发表于 2017-9-5 22:44
15年的总结?
出处是哪里?

FDA官网   

点评

哦哦哦,中文版网站》  详情 回复 发表于 2017-9-15 16:31
回复

使用道具 举报

发表于 2017-9-8 08:32:33 | 显示全部楼层
读后非常有收获
回复

使用道具 举报

药徒
发表于 2017-9-8 12:33:18 | 显示全部楼层
学习学习
回复

使用道具 举报

药徒
发表于 2017-9-15 16:31:21 | 显示全部楼层

哦哦哦,中文版网站》
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-6-7 02:54

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表